Eesti - eesti - Ravimiamet

sun pharmaceutical industries europe b.v. - amoksitsilliin+klavulaanhape - õhukese polümeerikattega tablett - 875mg+125mg 60tk; 875mg+125mg 30tk; 875mg+125mg 28tk; 875mg+125mg 24tk; 875mg+125mg 100tk; 875mg+125mg 8tk; 875mg+125mg 20tk; 875mg+125mg 12tk

Eesti - eesti - Ravimiamet

intervet international b.v. - florfenikool+fluniksiin - süstelahus - 300mg+16,5mg 1ml 100ml 1tk; 300mg+16,5mg 1ml 250ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - muud antineoplastilised ained - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastilised ained - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Eesti - eesti - Ravimiamet

qilu pharma spain s.l. - meropeneem - süste-/infusioonilahuse pulber - 1000mg 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

fondazione telethon ets - autoloogne cd34 + rakkude osa, mis sisaldab cd34 + rakkude transduced retroviiruse vektori, mis kodeerib inimeste adenosiini (ada) mida leidub cdna jada: inimese vereloome tüvirakkude vars/hindamist (cd34 +) rikastatud - raske kombineeritud immuunpuudulikkus - immunostimulants, - strimvelis on näidustatud tõttu adenosiin mida leidub puudusi (ada-scid), kombineeritud immuunpuudulikkusega patsientide raviks, kellele ei ole sobiva inimese leukotsüütide antigeeni (hla)-tasakaalustatud seotud tüvirakkude doonor on saadaval (vt lõik 4. 2 ja jaotis 4.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Euroopa Liit - eesti - EMA (European Medicines Agency)

vericel denmark aps - autoloogsed kultiveeritud kondrotsüüdid - luumurrud, kõhre - muud lihas-skeleti süsteemi häirete ravimid - põlve sümptomaatiliste täispaksuses remont.

Euroopa Liit - eesti - EMA (European Medicines Agency)

zoetis belgium sa - pirlimütsiin - antibakteriaalsed ravimid intramasinaalseks kasutamiseks - veised - ravi subclinical mastiit lakteerivate lehmade tõttu gram-positiivne cocci vastuvõtlikud pirlimycin sealhulgas stafülokoksete organismide, nagu staphylococcus aureus, nii penicillinase-positiivne ja penicillinase-negatiivne, ja koagulaasnegatiivsete stafülokokkide; streptokokk organismide, sh streptococcus agalactiae, streptococcus dysgalactiae ja streptococcus uberis.

Eesti - eesti - Ravimiamet

takeda pharma as - tetratsükliin - õhukese polümeerikattega tablett - 250mg 24tk